Galmed Pharmaceuticals Secures Patent for Aramchol, Enhancing NASH Combination Therapy Potential

Innovative Patent Grant Paves the Way for Combination Therapies in NASH Treatment

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical firm based in Ramot-Gan, Israel, recently announces the granting of a new Use Patent in South Korea for its lead compound, Aramchol. This patent complements existing protections granted in regions including the United States, Europe, and Canada, extending Aramchol's patent coverage until July 2042. As a first-in-class drug candidate that is poised for Phase 3 clinical trials, Aramchol has shown promising results in improving liver fibrosis in advanced clinical studies. The recent patent specifically covers the novel combination therapy of Aramchol with Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for treating non-alcoholic steatohepatitis (NASH), also recognized as metabolic dysfunction-associated steatohepatitis (MASH).

The patent grant is particularly timely, as the industry shifts towards more effective combination therapies to address the complexities of NASH/MASH, conditions that have historically been difficult to treat with existing monotherapies. CEO Allen Baharaff underscores Aramchol's exceptional safety and tolerability profile, making it a prime candidate for use in combination therapies aimed at treating these challenging liver diseases. This strategic focus not only positions Galmed Pharmaceuticals at the forefront of innovation in liver disease treatment but also highlights the growing recognition of the shortcomings of current single-agent therapies in the market.

As interest in MASH treatments escalates, Galmed Pharmaceuticals is committed to advancing its development of Aramchol, not only for liver diseases but also for potential applications in oncology and cardiometabolic conditions. The initiation of combination MASH clinical studies is deemed essential by the company, marking a significant advancement in treatment strategies. By exploring Aramchol’s potential in combination with other therapeutic agents, Galmed aims to offer more robust treatment options for patients suffering from NASH/MASH, ultimately contributing to improved health outcomes in this underserved patient population.

In addition to its developments in NASH/MASH therapies, Galmed Pharmaceuticals continues to explore a diverse pipeline targeting various other health conditions. The company remains focused on leveraging its innovative drug development capabilities to address unmet medical needs across multiple therapeutic areas. With the recent patent grant and the ongoing commitment to clinical advancement, Galmed is well-positioned to make significant contributions to the biopharmaceutical landscape.